Physician profile
Eva Sahay
NPI 1356453468
$905.03
in general payments reported to CMS, 2019-2025
15 companies · $79.77 in 2025
The $79.77 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $40.76 · 2021: $107 · 2022: $197 · 2023: $175 · 2024: $150 · 2025: $79.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $404.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $299.95 | 2022-2025 | Qulipta, Synthroid, Ubrelvy |
| Abbott Laboratories | $89.07 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $69.05 | 2021-2024 | Gvoke Hypopen |
| Medtronic, INC. | $67.18 | 2022-2024 | Percept PC Brainsense |
| Novo Nordisk INC | $63.39 | 2019-2025 | Ozempic |
| Biohaven Pharmaceutical Holding Company LTD. | $53.22 | 2022 | |
| Insulet Corporation | $44.45 | 2019-2021 | |
| Amgen INC. | $43.80 | 2019 | |
| Lilly USA, LLC | $42.36 | 2022-2023 | Jardiance |
| Pfizer INC. | $37.04 | 2023 | |
| Alfasigma USA, INC. | $23.45 | 2021 | |
| Biogen, INC. | $21.15 | 2021 | |
| Genzyme Corporation | $19.74 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.18 | 2021 | |
| Cequr Corporation | $15.00 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Sahay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.